

S.J. Enna	Editor-in-Chief: University of Kansas, USA
J.G. Piette	Editors: University of Liège, Belgium
G. Feuerstein	Wyeth Research, USA
M. Williams	Commentary Editor: Cephalon, Inc., USA

Biochemical Pharmacology Editorial Office

University of Kansas Medical Center, 3901 Rainbow Boulevard, Mail Stop 4016, Kansas City, Kansas 66160, USA, Tel: +1-913-588-7533, Fax: +1-913-588-7373, Email: BP@kumc.edu

EDITORIAL ADVISORY BOARD:

Antibiotics & Chemotherapeutics

B.B. Aggarwal	University of Texas M.D. Anderson Cancer Center, USA
C. Bailly	Institut de Recherche Pierre Fabre, France
S. Ceruti	University of Milano, Italy
B.S. Cummings	University of Georgia, USA
E. De Clercq	Catholic University of Leuven, Belgium
M. Diederich	Cancer and Blood Disease Research Foundation, Luxembourg
C. Elferink	University of Texas Medical Branch, USA
J.-M.A. Frere	University of Liège, Belgium
D.A. Gewirtz	Virginia Commonwealth University Massey Cancer Center, USA
O. Handa	Kyoto Prefectural University of Medicine, Japan
M.T. Rojewski	University of Ulm, Germany
B.A. Ruggeri	Cephalon, Inc., USA
G.L. Russo	National Research Council, Italy
B.A. Teicher	Genzyme Corporation, USA
K.D. Tew	Medical University of South Carolina, USA
F. Zunino	National Institute for the Study and Cure of Tumors, Italy

Cardiovascular

J.J. Badimon	Mount Sinai School of Medicine, USA
M.R. Bennett	University of Cambridge, UK
Y-H. Feng	Uniformed Services University of the Health Sciences, USA
B. M. Frey-von Matt	University of Bern, Switzerland
R.A. Khalil	Harvard Medical School, USA
D. Miller	Wyeth Research, USA
D. Newby	University of Edinburgh, UK
E.H. Ohlstein	GlaxoSmithKline Pharmaceuticals, USA
R.G. Schaub	Archemix Corporation, USA
B. Staels	University of Lille II, France
T. Unger	Charité Medical University of Berlin, Germany
R.J. Winquist	Vertex Pharmaceuticals, USA

Metabolic Disorders and Endocrinology

J.R. Colca	Kalamazoo Metabolic Research, USA
J. Pierre	INSERM U93-01, France
A. Kowluru	Wayne State University, USA
M.E. Poiriot	INSERM U563, France

Inflammation & Immunopharmacology

M.J. Alcaraz	University of Valencia, Spain
G.F. Babcock	University of Cincinnati Medical Center, USA
A. Bowie	Trinity College, Ireland
M.P. Fink	University of Pittsburgh, USA
K.B. Glaser	Abbott Laboratories, USA
J.J. Moreno	University of Barcelona, Spain
H.B. Pollard	Uniformed Services University of the Health Sciences, USA

Neuropharmacology

J. Bergman	Harvard Medical School, USA
D.C. Bertrand	University of Geneva, Switzerland
R.A.J. Challiss	University of Leicester, UK
C. Forray	Lundbeck Research USA
E.D. Hall	University of Kentucky Medical Center, USA
M.F. Jarvis	Abbott Laboratories, USA
M.J. Kuhar	Emory University, USA
R. Lewis	University of Queensland, Australia
M.J. Marino	Cephalon, Inc., USA
H. Möhler	University of Zurich, Federal Institute of Technology, Switzerland
A. Schousboe	Danish University of Pharmaceutical Sciences, Denmark
R.D. Spealman	Harvard University Medical School, USA
D.J. Triggle	State University of New York - Buffalo, USA
D. Weinschenker	Emory University, USA
J.M. Witkin	Lilly Corporate Center, USA

Pharmacokinetics & Drug Metabolism

K-I. Inui	Kyoto University Hospital, Japan
D.E. Mager	University at Buffalo, SUNY, USA
D.W. Nebert	University of Cincinnati, USA
B. Testa	University of Geneva, Switzerland

Toxicology

K.W. Bock	University of Tübingen, Germany
B.J. Day	National Jewish Medical and Research Center, USA
A.B. Okey	University of Toronto, Canada